IFLScience needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time.
Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results